The objective of this study is to describe the eligibility, consumption, efficacy and patient satisfaction when treating men with diabetes with Sildenafil. The study is a prospective, selfreported, flexible-dose study. In total, 45 patients with diabetes (type 1 or 2), complaining of erectile dysfunction, were treated with Sildenafil over a 12-week period. Efficacy was assessed using a patientlog, a general satisfaction questionnaire and the International Index of Erectile Function (IIEF). Of 326 men, 192 reported erectile dysfunction, 79 did not fulfil the criteria for Sildenafil treatment and 49 declined to participate. In the group of 33 (age 45-75 y, mean7s.d.: 58.177.2) completing the study, erectile function was significantly improved (Po0.0001). A total of 12 patients (36.4%) experienced no treatment effect at all. Eligibility and desire for treatment was low. Sildenafil is far from being a 'cure all' in the treatment of ED in diabetes.
Introduction
Erectile dysfunction (ED) is defined as the inability to achieve and maintain an erection sufficient for sexual intercourse. 1 The problem is common, with an overall prevalence of ED in the general population between the ages of 40 and 70 y around 50%. 2 ED is an important cause of decreased quality of life particularly with respect to emotional functioning, 3 and a common complication of both type 1 and type 2 diabetes in men, with a prevalence ranging from 20 to 85% in all ages. [4] [5] [6] [7] [8] [9] [10] [11] ED affects diabetic men 10-15 y earlier than the general population. 4 In men with type 2 diabetes, glycemic control and peripheral neuropathy are independent predictors of ED. 12 Sildenafil has been shown to be an effective and well-tolerated treatment in patients with ED of various etiologies, [13] [14] [15] including ED in diabetes. [16] [17] [18] [19] [20] The use of Sildenafil for ED in diabetes is restricted by the fact that the drug cannot be used for patients with significant heart-or peripheral vascular disease or patients using nitrates, and it requires at least a partially intact penile nervous system. 14 In 1997-1998, the majority of the diabetic population in the outpatients department at Bispebjerg Hospital participated in a questionnaire study, which showed an overall prevalence of ED of 59%. 21 In reviewing the data, the following questions emerged: How many of these patients, if approached, actually want to try treating the problem? How many are eligible for treatment, especially considering the abundance of cardio-and peripheral vascular disease in the population? What is the efficacy of the treatment, measured with a validated instrument for self-registering sexual function? And finally, how do these results relate to late onset diabetic complications, hypertension and psychosocial factors, available from the questionnaire study.
Research design and methods

Bispebjerg Hospital diabetes questionnaire study
In the period from November 1997 to June 1998, 560 consecutive patients (326 men and 234 women) attending the diabetic outpatients clinic at Bispebjerg Hospital, Copenhagen, participated in a large clinical epidemiological questionnaire study, and 468 of these patients (277 men and 191 women) went on to participate in a structured interview.
The primary purpose of this two-step study was to estimate the prevalence of diabetic neuropathy and some of its manifestations: gastroenteropathy, peripheral neuropathy and ED. Extensive data were obtained regarding these manifestations, along with data regarding general health, diabetes duration and regulation, psychosocial factors, self-care behavior and medication, late onset complications, educational and employment status, weight and exercise habits, and present and previous illnesses. Clinical data included BMI, Hb, HbA1c, lipid profile, blood pressure, urine albumin, creatinine and ECG.
Patients
Of the 326 men with either type 1 or type 2 diabetes who participated in the questionnaire study, 192 (58.8%) reported ED (defined as trouble obtaining or sustaining an erection) of more than 6 months duration. Of the 192 patients who were over the age of 40 y, 187 were considered for this study (Figure 1 ). Before patients were approached, all patient files were reviewed by the project responsible doctor, and 69 of the 187 patients were excluded, mainly due to cardiovascular disease and also based on the following criteria: stroke or myocardial infarction within the last 6 months, proliferative diabetic retinopathy, simultaneous treatment with nitrates, anticoagulants, estrogens or androgens, potentially lethal concomitant disease (eg, cancer), uncontrolled psychiatric disease or known drug or alcohol abuse.
The remaining 118 suitable patients were invited by letter to participate. A total of 14 patients did not respond to the invitation and 49 declined to participate. In all, 55 patients (46%) were scheduled for screening. At the screening visit, three patients did not attend as scheduled and seven were excluded: two because of treatment with nitrates, two because they were already using Sildenafil and three because of cardiovascular disease. Thus, 45 patients were included in the study.
Study design
The study was carried out as a prospective, selfreported, flexible-dose study. Approval of the study protocol was obtained from the local Ethics Committee (journal number (KF)02-090/99), and all patients gave their written informed consent. Eligible patients were screened (baseline, week 0) by the project doctor, and the following data were obtained: medical history and demographic information, updated list of medication, vital signs, clinical examination, 12-lead ECG, ophthalmoscopy and biothesiometry, if these had not been carried out within the last year.
The investigator provided the patient with Sildenafil tablets, along with instruction on use and adjustment of dose depending on effect and adverse events. The starting dosage of Sildenafil depended on the age of the patient: 25 mg for patients 65 y and older and 50 mg for patients under the age of 65 y. The maximal dose was 100 mg/24 h. During the following 12-week intervention period, patients had access to unlimited telephone consultations with the doctor. Patients who initially responded to the written invitation, but did not want to participate, returned a short questionnaire explaining reasons why.
Outcome measures
The efficacy of the treatment was assessed using a validated Danish translation of the self-administered 326 men with type 1 or type 2 diabetes participated in the Bispebjerg Hospital diabetes questionnaire study.
187 men > 10 complaining of ED of more than 6 months duration considered for the study.
118 men invited to participate in the study. Sildenafil for ED in diabetes L Behrend et al 'International Index of Erectile Function' (IIEF) 22 at baseline and week 12. The IIEF is a 15-question instrument that addresses the relevant domains of male sexual function. Responses assess treatment outcomes for the previous 4 weeks, and are scored using a five-point ordered, categorical scale, with a score of 1 representing the worst response (almost never/never), and a score of 5 representing the best response (almost always/always). Where applicable, a score of 0 indicates no attempt at sexual activity/ intercourse. The 15 questions fall into five domains of sexual function: erectile function (questions 1-5 and 15), orgasmic function (questions 9-10), sexual desire (questions 11-12), intercourse satisfaction (questions 6-8) and overall satisfaction (questions [13] [14] . Domain scores are computed by summing up the scores for individual items in each domain, and a total IIEF score is also calculated.
Patients also kept an event log, registering dosage, attempts at sexual activity, successful attempts and adverse events. At week 12, patients filled out a short questionnaire concerning general satisfaction with the treatment, side effects or other problems with the treatment and intention to continue use in the future.
Follow-up
For patients who wished to continue treatment, the general satisfaction questionnaire was repeated at 6 and 12 months after visit 2.
Statistical analysis
All data processing was carried out with the SPSS 10.0 software. Comparison of participants and nonparticipants and comparison of IIEF scores before and after treatment were carried out by Mann-Whitney U-test, independent-samples t-test and the Pearson w 2 test. The P-values less than 0.05 were regarded statistically significant. In a logistic regression analysis, each independent variable was analyzed in a univariate model and if the significance level was o10%, the variable was included in a multivariate model. Continuous variables were tested for linearity, and if not linear categorized.
Results
Participation, dosage and side effects A total of 118 male patients were invited to participate in the study; 49 patients declined to participate, predominant reasons being age (44.9%) and concomitant disease (28.6%). Of the 55 patients scheduled for screening, 45 could be enrolled in the study. A total of 12 patients (26.7%) dropped out, 10 because they had had no opportunity to use Viagra, two gave no reason.
Characteristics of included and excluded patients are shown in Table 1 
A total of 33 patients, age 45-75 y (mean7s.d.: 58.177.2), completed the study. In all, 12 patients (36.4%) had type 1 diabetes, and the remaining 21 (63.6%) had type 2 diabetes. Six (28.6%) of the patients with type 2 diabetes were insulin treated. Only 18 patients (54.5%) felt that they were impotent (defined as a subjective perception of impotence). After the run-in period, 20 patients (60.6%) received the maximal dose of 100 mg/24 h.
A total of 12 patients (36.4%) reported side effects, but only one had to discontinue treatment (because of a suspected mild allergic reaction). Four patients reported dizziness (12.1%), six patients reported headache (18.2%), six patients reported hot flashes (18.2%), two patients had heartburn (6.1%) and one had nausea (3%) in relation to using the drug.
Treatment effect
A total of 12 patients (36.4%) could report satisfactory treatment effect every time they used Viagra after the initial dose adjustment, nine patients (27.2%) had varied effect and the remaining 12 patients (36.4%) experienced no treatment effect at all, even at maximal doses. IIEF domain scores for the 33 patients who completed the study are seen in Table 2 . The following scores were significantly improved during treatment with Sildenafil (Po0.0001): erectile function, intercourse satisfaction, overall satisfaction and total IIEF score. In total, 18 patients (54.5%) felt the treatment had met their expectations. Treatment effect and satisfaction was tested against and found not to be related to the following variables: age, HbA1c, duration of diabetes, duration of ED, BMI, smoking, alcohol consumption, sense of vibration (biothesiometry), psychologic vulnerability, urinary albumin content and pathological ECG.
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Discussion
In reviewing the literature, we found five studies that examine the treatment of ED in diabetes with Sildenafil, [16] [17] [18] [19] [20] of which the study by Rendell et al 17 is still the most important. They found that
Sildenafil improved erections in 56% of patients with no effect on orgasmic function or sexual desire scores, and that 16% of patients had adverse events. Price et al 18 found improved erections in 52% of patients using 50 mg of Sildenafil, and Palumbo et al 19 in the most recent study found a 'response' of 69% in patients with diabetes. Earlier studies of ED in diabetes rarely distinguish between diabetes types. [6] [7] Two of the previous studies of Sildenafil for ED in diabetes are quite small, 18, 20 and two do not use validated measures of erectile function. [18] [19] Two of the studies require patients to have a stable sexual relationship of at least 6 months, 17, 20 and in the article by Rendell et al 17 even stipulates that the partner must be female. This restriction has been commented on by the authors 23 and is related to the use of the IIEF, but even so should be looked on critically. A good dialog in these matters relies heavily on acceptance of sexual diversity, and these 24 are those concerning previous ketoacidocis, glycemic control prior to and at the time of screening and severe autonomic neuropathy. These restrictions result in a very selected study population.
Sildenafil significantly improved erectile function and intercourse satisfaction in men with type 1 or type 2 diabetes and ED. We found that treatment success or failure could be assessed through selfadministered dose adjustment with a written guide. Side effects were mild, with a prevalence comparable to those found in studies of ED in men without diabetes. [13] [14] [15] Only half the patients with ED felt that they were 'impotent', which strongly supports the use of a layman's term equivalent to ED instead of impotence, when addressing the problem with patients. None of the extensive range of variables in the Bispebjerg Hospital epidemiological questionnaire database was associated with treatment effect or satisfaction with Sildenafil.
The study was carried out in a realistic outpatient setting with no restrictions concerning age, glycemic control, marital status or sexual preference. Medication was free, however, and this undoubtedly increased the willingness to both try and continue with the treatment. Price is a factor that the patients take into consideration with this treatment. The method of self-adjustment and -evaluation was effective and user friendly, and can therefore be recommended as part of the initiation of Sildenafil treatment or any other attempt to improve erectile function. Just as in the case of self-registration and reporting of blood glucose, it will facilitate a qualified dialog between the patient and the diabetes team. Efficacy was measured using a validated instrument that addresses the relevant domains of male sexual function. The only limitation we found in using the IIEF was the consistent use of ability to have intercourse as the golden standard for erectile and sexual function. This limitation is rooted in the definition of ED and in our opinion creates an unnecessary restriction.
A substantial group (nonparticipants) was either excluded, primarily due to cardiovascular disease, or declined to participate in the study when given the offer. Predominant reasons for declining to participate were age and concomitant illness. The nonparticipant group was expectedly older, with longer duration of ED and more frequent pathological ECG, but otherwise did not differ from those included on a range of clinical and biochemical variables. The dropout rate was high, mainly because having a sexual partner at baseline was not a criterion for eligibility. Patients who in the 12 weeks had no opportunity to use Viagra, apparently chose to drop out instead of completing a somewhat futile visit 2.
Conclusions
In the large unselected group of men with type 1 or type 2 diabetes and ED in the study we have reported, both eligibility and desire for treatment with Sildenafil were low. In the select group who completed the treatment, Sildenafil significantly improved erectile function and proved easy and safe to use. This, to some extent, answers the questions set forth by Lipschultz and Kim. 24 The fact that only 33 patients completed the study, although comprising a weakness statistically, is also an important result in itself, demonstrating that factors such as demand and eligibility play an important role when introducing a treatment such as this in a population with a chronic disease. It is just as important to know that Sildenafil seems to work when accepted in patients without the complications listed as contraindications. However, for many or most, other counseling efforts including alternative treatment possibilities will be necessary. This counseling is well within the scope of a motivated diabetes team.
